Rodman & Renshaw Initiates Coverage on Telomir Pharmaceuticals (NASDAQ:TELO)

Stock analysts at Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals (NASDAQ:TELO) in a report released on Friday, MarketBeat reports. The firm set a “buy” rating and a $15.00 price target on the stock. Rodman & Renshaw’s target price would suggest a potential upside of 283.63% from the stock’s current price.

Telomir Pharmaceuticals Stock Down 6.5 %

Shares of NASDAQ TELO opened at $3.91 on Friday. The business has a fifty day simple moving average of $4.54 and a two-hundred day simple moving average of $4.86. The firm has a market cap of $116.36 million and a PE ratio of -6.74. Telomir Pharmaceuticals has a twelve month low of $3.11 and a twelve month high of $9.54.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). On average, research analysts expect that Telomir Pharmaceuticals will post -0.4 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Gotham Asset Management LLC purchased a new position in Telomir Pharmaceuticals during the 4th quarter worth $28,000. Barclays PLC grew its stake in Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock valued at $45,000 after purchasing an additional 5,367 shares during the last quarter. Rhumbline Advisers grew its stake in Telomir Pharmaceuticals by 105.9% during the 4th quarter. Rhumbline Advisers now owns 8,600 shares of the company’s stock valued at $35,000 after purchasing an additional 4,424 shares during the last quarter. Corebridge Financial Inc. grew its stake in Telomir Pharmaceuticals by 273.8% during the 4th quarter. Corebridge Financial Inc. now owns 9,613 shares of the company’s stock valued at $40,000 after purchasing an additional 7,041 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in Telomir Pharmaceuticals by 458.3% during the 4th quarter. Wells Fargo & Company MN now owns 10,044 shares of the company’s stock valued at $41,000 after purchasing an additional 8,245 shares during the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.